SAN DIEGO--(BUSINESS WIRE)--Aug. 2, 2018--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) (“Tandem”), a medical device
company and manufacturer of the only touchscreen insulin pumps available
in the United States, today announced that it has commenced a proposed
underwritten public offering of its common stock. All of the shares to
be sold in the offering will be offered by Tandem. In addition, Tandem
expects to grant to the underwriters a 30-day option to purchase up to
15 percent of the offering in additional common stock. The number of
shares to be offered and the price per share have not yet been
determined. The offering will be subject to market conditions and other
factors and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the offering.
Oppenheimer & Co. Inc. is acting as the sole book‐running manager for
the offering.
This offering is being made pursuant to a shelf registration statement
on Form S-3 that was filed by Tandem with the Securities and Exchange
Commission and declared effective on May 9, 2018. A preliminary
prospectus supplement and accompanying prospectus describing the terms
of the proposed offering will be filed with the Securities and Exchange
Commission and will form a part of the effective registration statement.
When available, copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the securities being offered may be
obtained from: Oppenheimer & Co. Inc. Attention: Syndicate Prospectus
Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone
at (212) 667-8055 or by email at EquityProspectus@opco.com.
Electronic copies of the preliminary prospectus supplement and
accompanying prospectus will also be available on the Securities and
Exchange Commission’s website at www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any
such state or jurisdiction. The offering will be made only by means of a
prospectus that forms a part of the registration statement.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. Tandem takes an innovative, user-centric approach to the
design, development and commercialization of products for people with
diabetes who use insulin. Tandem manufactures and sells the t:slim X2™
Insulin Pump with Basal-IQ™ technology. The t:slim X2 Pump is capable of
remote feature updates using a personal computer, and is the first
insulin pump designated as compatible with integrated continuous glucose
monitoring (iCGM) devices. Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark, and t:slim X2 and
Basal-IQ are trademarks of Tandem Diabetes Care, Inc.
Forward Looking Statements
This press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
include statements regarding the Company’s expectations regarding the
sales of shares in the proposed offering, including the anticipated
amount to be raised in the offering, and other statements that are not
purely statements of historical fact. Such forward-looking statements
are based on the Company’s current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual results,
and the timing of events, may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including the uncertainties regarding market conditions and the
completion of the underwritten offering on the anticipated terms or at
all. Other risks and uncertainties are identified in the Company’s most
recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and
other documents that the Company files with the Securities and Exchange
Commission including the Registration Statement on Form S-3 for the
offering. Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release. Unless otherwise required by applicable law or the rules of the
NASDAQ Stock Market, Tandem undertakes no obligation to update or revise
any forward-looking statement in this press release because of new
information, future events or other factors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180802005861/en/
Source: Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc.
Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com
or
Investor
Contact:
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com
